gptkbp:instance_of
|
gptkb:psychologist
|
gptkbp:bfsLayer
|
3
|
gptkbp:bfsParent
|
gptkb:Stephen_Hawking
gptkb:Lou_Gehrig
|
gptkbp:affects
|
motor neurons
|
gptkbp:caused_by
|
death of motor neurons
|
gptkbp:clinical_trial
|
ongoing
|
gptkbp:current_use
|
gptkb:frontotemporal_dementia
pain
spasticity
|
gptkbp:environmental_impact
|
smoking
exposure to toxins
|
gptkbp:famous_person
|
gptkb:Jason_Becker
gptkb:A._J._Styles
gptkb:Pat_Quinn
gptkb:Steve_Gleason
gptkb:Stephen_Hawking
gptkb:Timothy_Green
gptkb:Morrissey
gptkb:Lou_Gehrig
gptkb:David_Niven
Glen Mc Mahon
|
gptkbp:first_described_by
|
gptkb:Jean-Martin_Charcot
|
gptkbp:genetic_diversity
|
C9orf72 mutations
SO D1 mutations
|
https://www.w3.org/2000/01/rdf-schema#label
|
amyotrophic lateral sclerosis
|
gptkbp:is_involved_in
|
gptkb:ALS_Therapy_Development_Institute
gptkb:ALS_Association
gptkb:MDA_(Muscular_Dystrophy_Association)
|
gptkbp:is_known_for
|
gptkb:Lou_Gehrig's_disease
|
gptkbp:is_popular_in
|
2 per 100,000 people
|
gptkbp:premiered_on
|
typically between ages 40 and 70
|
gptkbp:research
|
ongoing studies
|
gptkbp:social_responsibility
|
clinical examination
varies by individual
electromyography
|
gptkbp:symptoms
|
respiratory failure
difficulty speaking
muscle weakness
difficulty swallowing
muscle atrophy
|
gptkbp:treatment
|
gptkb:riluzole
gptkb:edaravone
supportive care
|